BMY · Bristol Myers Squibb Co · Earnings Call Transcripts & Audio
$62.40
-0.46 (-0.73%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$128.41B
Shares
2.04B
Volume · Sep 30
15.87M
Avg daily vol (3M)
11.02M
Bristol Myers Squibb Co Earnings Call Transcripts
Quarterly earnings calls for Bristol Myers Squibb Co (BMY), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼4.8%
$11.41B
$2.02B
'22 Q4
23-02-02
▼2.7%
$11.34B
$2.26B
'23 Q1
23-04-27
▼5.6%
$11.23B
$2.07B
'23 Q2
23-07-27
▼2.2%
$10.97B
$1.93B
'23 Q3
23-10-26
▲0.6%
$11.48B
$1.76B
'23 Q4
24-02-02
▲4.7%
$11.87B
−$11.91B
'24 Q1
24-04-25
▲8.7%
$12.20B
$1.68B
'24 Q2
24-07-26
▲8.4%
$11.89B
$1.21B
'24 Q3
24-10-31
▲7.5%
$12.34B
$72.00M
'24 Q4
25-02-06
▼5.6%
$11.20B
$2.46B
'25 Q1
25-04-24
▲0.6%
$12.27B
$1.31B
'25 Q2
25-07-31
▲2.8%
$12.22B
$2.20B
'25 Q3
25-10-30
▲1.3%
$12.50B
$1.09B
'25 Q4
26-02-05
▲2.6%
$11.49B
$2.68B
'26 Q1
26-04-30
LATEST
▲5.7%
$12.97B
$3.32B
'26 Q2
26-07-30
Earnings call
FY26 · Q3
2026-10-29
Bristol Myers Squibb Co (BMY) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-07-30
Bristol Myers Squibb Co (BMY) Q2 2026 Earnings Call Transcript
Confident tone
Regulatory milestones and launches
Pipeline and pivotal readouts
Cobenfy / ADEPT program delays
Revenue
$12.97B
▲ 5.7% YoY Diluted EPS
$1.62
▲ 153.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Bristol Myers Squibb Co (BMY) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Bristol Myers Squibb Co (BMY) Q1 2026 Earnings Call Transcript
Confident tone
Admilperent (LPA1) in IPF and PPF
Growth portfolio performance
Capital allocation, business development, cost savings
Revenue
$11.49B
▲ 2.6% YoY Diluted EPS
$1.31
▲ 9.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-05
Bristol Myers Squibb Co (BMY) Q4 2025 Earnings Call Transcript
Positive tone
Legacy portfolio decline / LOE
Growth portfolio momentum
Key growth brands
Revenue
$12.50B*
▲ 1.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Bristol Myers Squibb Co (BMY) Q3 2025 Earnings Call Transcript
Confident tone
Cobenfy launch and Alzheimer's psychosis
Growth portfolio performance
Business development and partnerships
Revenue
$12.22B
▲ 2.8% YoY Diluted EPS
$1.08
▲ 80% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Bristol Myers Squibb Co (BMY) Q2 2025 Earnings Call Transcript
Positive tone
New product launches
Pipeline catalysts and lifecycle management
Capital deployment and business development
Revenue
$12.27B
▲ 0.6% YoY Diluted EPS
$0.64
▼ 22.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-24
Bristol Myers Squibb Co (BMY) Q1 2025 Earnings Call Transcript
Positive tone
Business development and capital allocation
Tariffs and policy uncertainty
Growth portfolio and Q1 performance
Revenue
$11.20B
▼ 5.6% YoY Diluted EPS
$1.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-06
Bristol Myers Squibb Co (BMY) Q4 2024 Earnings Call Transcript
Confident tone
Cobenfy launch and lifecycle
Pipeline catalysts and R&D productivity
Growth portfolio performance
Revenue
$12.34B*
▲ 7.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Bristol Myers Squibb Co (BMY) Q3 2024 Earnings Call Transcript
Confident tone
Cobenfy launch and schizophrenia opportunity
Milvexian atrial fibrillation trial
Growth portfolio performance
Revenue
$11.89B
▲ 8.4% YoY Diluted EPS
$0.60
▼ 35.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-26
Bristol Myers Squibb Co (BMY) Q2 2024 Earnings Call Transcript
Confident tone
KarXT Launch Preparation
Policy and IRA Risk
Capital Allocation and Business Development
Revenue
$12.20B
▲ 8.7% YoY Diluted EPS
$0.83
▼ 16.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-25
Bristol Myers Squibb Co (BMY) Q1 2024 Earnings Call Transcript
Positive tone
Commercial portfolio performance
Inflation Reduction Act (IRA)
Pipeline advancement and cell therapy
Revenue
$11.87B
▲ 4.7% YoY Diluted EPS
$-5.89
▼ 650.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-02
Bristol Myers Squibb Co (BMY) Q4 2023 Earnings Call Transcript
Positive tone
Commercial performance of growth brands
Eliquis and IRA price negotiations
Financial guidance and margin discipline
Revenue
$11.48B*
▲ 0.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
Bristol Myers Squibb Co (BMY) Q3 2023 Earnings Call Transcript
Revenue
$10.97B
▼ 2.2% YoY Diluted EPS
$0.93
▲ 24% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-27
Bristol Myers Squibb Co (BMY) Q2 2023 Earnings Call Transcript
Revenue
$11.23B
▼ 5.6% YoY Diluted EPS
$0.99
▲ 50% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Bristol Myers Squibb Co (BMY) Q1 2023 Earnings Call Transcript
Revenue
$11.34B
▼ 2.7% YoY Diluted EPS
$1.07
▲ 81.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-02
Bristol Myers Squibb Co (BMY) Q4 2022 Earnings Call Transcript
Revenue
$11.41B*
▼ 4.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Bristol Myers Squibb Co (BMY) Q3 2022 Earnings Call Transcript
Revenue
$11.22B
▼ 3.5% YoY Diluted EPS
$0.75
▲ 8.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-27
Bristol Myers Squibb Co (BMY) Q2 2022 Earnings Call Transcript
Revenue
$11.89B
▲ 1.6% YoY Diluted EPS
$0.66
▲ 40.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-29
Bristol Myers Squibb Co (BMY) Q1 2022 Earnings Call Transcript
Revenue
$11.65B
▲ 5.2% YoY Diluted EPS
$0.59
▼ 33.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-04
Bristol Myers Squibb Co (BMY) Q4 2021 Earnings Call Transcript
Revenue
$11.98B*
▲ 8.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Bristol Myers Squibb Co (BMY) Q3 2021 Earnings Call Transcript
Revenue
$11.62B
▲ 10.3% YoY Diluted EPS
$0.69
▼ 15.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Bristol Myers Squibb Co (BMY) Q2 2021 Earnings Call Transcript
Revenue
$11.70B
▲ 15.5% YoY Diluted EPS
$0.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Bristol Myers Squibb Co (BMY) Q1 2021 Earnings Call Transcript
Revenue
$11.07B
▲ 2.7% YoY Diluted EPS
$0.89
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-04
Bristol Myers Squibb Co (BMY) Q4 2020 Earnings Call Transcript
Revenue
$11.07B
▲ 39.3% YoY Diluted EPS
$-4.45
Gross margin
73.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Bristol Myers Squibb Co (BMY) Q3 2020 Earnings Call Transcript
Revenue
$10.54B
▲ 75.5% YoY Diluted EPS
$0.82
▼ 1.2% YoY Gross margin
76.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Bristol Myers Squibb Co (BMY) Q2 2020 Earnings Call Transcript
Revenue
$10.13B
▲ 61.5% YoY Diluted EPS
$-0.04
▼ 104.6% YoY Gross margin
73.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Bristol Myers Squibb Co (BMY) Q1 2020 Earnings Call Transcript
Revenue
$10.78B
▲ 82.1% YoY Diluted EPS
$-0.34
▼ 132.7% YoY Gross margin
66.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-06
Bristol Myers Squibb Co (BMY) Q4 2019 Earnings Call
Revenue
$7.95B
▲ 33% YoY Diluted EPS
$-0.55
▼ 177.5% YoY Gross margin
68.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 earnings calls